In a significant development for the treatment of schizophrenia, the FDA has recently approved Cobenfy, a novel medication that targets schizophrenia through non-dopaminergic pathways. This…
Introducing KarXT: A New Paradigm on May 1, 2024, JAMA Psychiatry published the positive results of EMERGENT-3 trials for this potential non-dopaminergic medication for schizophrenia. …
Facebook LIVE 003: Join us for our third Facebook Live[May 18 at 10:30 am PST] Facebook LIVE is a new feature for our academy students.…
Clozapine, a cornerstone in the treatment of treatment-resistant schizophrenia, is known for its efficacy in patients who have not responded to other antipsychotic medications. However,…
PSYCHIATRY EDUCATION FORUM ACADEMY’S JOURNAL CLUB 24: 50 Years of Research on Schizophrenia: Ascendance of the Glutamatergic Synapse It is important to reflect on the…
Cannabis use is a highly debated topic in the medical community, and it has been linked to a range of physical and psychological problems, including…
Clozapine is considered a gold-standard medication for treatment-resistant schizophrenia, but close to 50% of these patients on clozapine may show poor or no response. What…
Clozapine is considered a gold-standard medication for treatment-resistant schizophrenia, but close to 40-50% of these patients on clozapine may show poor or no response. What…
Psychiatry Education Forum Academy is excited to release our next journal club discussion today. This journal club will focus on this clinically relevant topic of…
BEFORE SCROLLING DOWN ==> SUBMIT YOUR ANSWERS FIRST 🙂 There is growing evidence that patients with comorbid obsessive-compulsive disorder (OCD) and schizophrenia may represent a…
Clozapine is considered a gold-standard medication for treatment-resistant schizophrenia, but close to 50% of these patients on clozapine may show poor or no response. What…
Sep 01, 2021. Today FDA approved the first and only 6 monthly long-acting injectable for schizophrenia treatment: Invega Hafyera. We have summarized Invega Hafyera clinical…
Today we posted the sixth and seventh journal club in PEFA Journal Club’s discussion series, discussing the following two newer antipsychotics for schizophrenia treatment: (A)…
Today we posted the following fifth journal club in PEFA Journal Club’s discussion series and discussion with a expert in our Coffee Club’s discussion section:…
Today we posted the following fourth journal club in PEFA Journal Club’s discussion series: Journal Club #4: Staging of Schizophrenia With the Use of PANSS:…
June 01, 2021 Today FDA approved LYBALVI for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed…
Today (May 24) is World Schizophrenia Day. The purpose of this day is to increase awareness and reduce the stigma associated with the diagnosis of…
Lumateperone is the most recently approved FDA-approved medication for the treatment of schizophrenia. Watch the following short video discussion from our journal club regarding the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
